Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Ovarian Neoplasms

Free Subscription 15.12.2025 2 Ann Oncol 2 BMC Cancer 1 Clin Cancer Res 3 Eur J Obstet Gynecol Reprod Biol 19 Gynecol Oncol 1 Int J Oncol 1 Mol Ther Oncol 1 Oncogene 1 Oncology (Williston Park)

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Oncol

1. LEDERMANN JA, Coleman RL
   The PARP inhibitor/Immunotherapy Paradox in Advanced Ovarian Cancer: Positive Endpoints, Perplexing Interpretations.
   Ann Oncol. 2025 Dec 10:S0923-7534(25)06318-5. doi: 10.1016/j.annonc.2025.
   PubMed        
   
   
2. HARTER P, Trillsch F, Okamoto A, Reuss A, et al
   Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.
   Ann Oncol. 2025 Dec 9:S0923-7534(25)06315-X. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   

   
   BMC Cancer

3. CHEN Q, Dorji JP, Perera SG, Li P, et al
   In vivo inhibition of c-MYC in the metastatic drug-resistant ovarian cancer cells down regulates the c-MYC-PD-L1-PAX8-p21 to achieve therapeutic efficacy.
   BMC Cancer. 2025 Dec 10. doi: 10.1186/s12885-025-15435.
   PubMed         Abstract available
   
   
4. CHEN L, Ji H, Xie Z, Lin Y, et al
   miR-101-3p represses the migratory and invasive abilities of ovarian cancer cells.
   BMC Cancer. 2025;25:1864.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

5. HOLLIS RL, Miller A, Lankes HA, Wong KK, et al
   Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancer.
   Clin Cancer Res. 2025 Dec 11. doi: 10.1158/1078-0432.CCR-25-3042.
   PubMed         Abstract available
   
   

   
   Eur J Obstet Gynecol Reprod Biol

6. WONG Y, Fong KY, Lim SK, Nadarajah R, et al
   vNOTES retroperitoneal sentinel lymph node biopsy and pelvic lymph node dissection for surgical staging of endometrial cancer: A single-center experience.
   Eur J Obstet Gynecol Reprod Biol. 2025;316:114838.
   PubMed         Abstract available
   
   
7. DICK A, Lessans N, Cohen N, Gutman-Ido E, et al
   Distinguishing mature from immature ovarian teratoma in the pre-operative setting.
   Eur J Obstet Gynecol Reprod Biol. 2025;316:114793.
   PubMed         Abstract available
   
   
8. CASANOVA J, Ramos AS, Babiciu A, Moutinho F, et al
   Prevalence of high-grade endometrioid endometrial cancer of no specific molecular profile (NSMP): A systematic review and meta-analysis.
   Eur J Obstet Gynecol Reprod Biol. 2025;316:114794.
   PubMed         Abstract available
   
   

   
   Gynecol Oncol

9. WASHINGTON C, Dwivedi SKD, Gunderson-Jackson C, Walker J, et al
   Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.
   Gynecol Oncol. 2025;203:158-164.
   PubMed         Abstract available
   
   
10. FAN Y, Wang Q, Deng H, Liu Y, et al
    Neoadjuvant chemotherapy modulates mast cell phenotypes and immune infiltration in high-grade serous carcinoma.
    Gynecol Oncol. 2025;203:119-129.
    PubMed         Abstract available
    
    
11. WHITE VM, Langdale LM, Eroh KD, Ackermann MK, et al
    Experiences of radiotherapy for treatment of Granulosa Cell Tumor of the ovary: insights from the GCT-survivor sisters.
    Gynecol Oncol. 2025;203:112-118.
    PubMed         Abstract available
    
    
12. SKOLD C, Radestad AF, Bohlin KS, Bjurberg M, et al
    Primary treatment and survival in malignant ovarian germ cell tumors: A nationwide population-based Swedish Gynecologic Cancer Group (SweGCG) study.
    Gynecol Oncol. 2025;203:59-66.
    PubMed         Abstract available
    
    
13. MACHIDA H, Kawana K, Okamoto A, Yamagami W, et al
    Impact of neoadjuvant chemotherapy followed by interval debulking surgery on survival in women with advanced non-serous ovarian, fallopian tube, or primary peritoneal cancer.
    Gynecol Oncol. 2025;203:8-15.
    PubMed         Abstract available
    
    
14. HOLTZMAN S, Myers E, Havrilesky LJ, Yamada D, et al
    Gynecologic oncology fellowship trends: Supply outpacing demand, geographical maldistribution.
    Gynecol Oncol. 2025;202:162-166.
    PubMed         Abstract available
    
    
15. DAGHER C, Selenica P, Bakhuis CFJ, Green H, et al
    Prognostic value of positive peritoneal cytology in FIGO 2009 stage IA grade 1 endometrioid endometrial cancer.
    Gynecol Oncol. 2025;202:154-161.
    PubMed         Abstract available
    
    
16. KIM U, Oh BC, Bae J, Kang S, et al
    Survival outcomes and treatment patterns in malignant ovarian sex cord-stromal tumors: A population-based analysis.
    Gynecol Oncol. 2025;202:146-153.
    PubMed         Abstract available
    
    
17. BORDEN BA, Rodriguez-Hernandez A, Trottier M, Horiguchi M, et al
    SMARCA4 pathogenic variants: Gynecological cancer histories from a laboratory tested cohort.
    Gynecol Oncol. 2025;202:125-130.
    PubMed         Abstract available
    
    
18. CHUNG YE, Kim SI, Noh JJ, Lee JY, et al
    Immune checkpoint inhibitors for recurrent ovarian clear cell carcinoma: Real-world outcomes from a Korean multicenter study.
    Gynecol Oncol. 2025;203:185-190.
    PubMed         Abstract available
    
    
19. LEE AJ, Jang EB, Suh DH, Chang SJ, et al
    Comparison of oncologic outcomes between completion hysterectomy and no completion hysterectomy in patients who achieved complete response and completed childbearing after fertility-sparing treatment for early-stage endometrial cancer: Gynecologic Onc
    Gynecol Oncol. 2025;203:191-197.
    PubMed         Abstract available
    
    
20. KRAICZY J, Yu B
    Human fallopian tube epithelial organoids with TP53 mutation recapitulate features of serous tubal intraepithelial carcinoma (STIC).
    Gynecol Oncol. 2025;203:198-208.
    PubMed         Abstract available
    
    
21. HANSEN J, Suratkal J, Shah SN, Kelley J, et al
    Frailty and body composition as predictors of postoperative outcomes in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy.
    Gynecol Oncol. 2025;204:143-149.
    PubMed         Abstract available
    
    
22. WANG Y, Van Nieuwenhuysen E, Revheim ME, Deroose CM, et al
    First experience with intraperitoneal (224)Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer.
    Gynecol Oncol. 2025;204:158-164.
    PubMed         Abstract available
    
    
23. EVANS HE, Firriolo AM, Houweling R, Kelada L, et al
    Evaluating patient perspectives about the acceptability of a novel prognostic gene expression signature for high grade serous ovarian cancer: The OTTA-SPOT study.
    Gynecol Oncol. 2025;204:150-157.
    PubMed         Abstract available
    
    
24. NAKAYAMA J, McGaughey M, Pindzola G, Miller E, et al
    Machine-learning survival models for predicting time to recurrence in epithelial ovarian cancer.
    Gynecol Oncol. 2025;204:184-193.
    PubMed         Abstract available
    
    
25. PEPLINSKI RM, Riordan JD, Schillo JL, Hannan EC, et al
    Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell lines.
    Gynecol Oncol. 2025;204:194-201.
    PubMed         Abstract available
    
    
26. SHAHIN MS, Mathur R, Parthan A, Yerram P, et al
    Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS).
    Gynecol Oncol. 2025;204:202-209.
    PubMed         Abstract available
    
    
27. WASHINGTON C, Pothuri B, Cadoo K, Drew Y, et al
    Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review.
    Gynecol Oncol. 2025;204:218-227.
    PubMed         Abstract available
    
    

    
    Int J Oncol

28. WANG F, Xu X, Guan B, Li X, et al
    Regulation and reversal of paclitaxel resistance via the STAT1?mediated apoptotic pathway in ovarian cancer.
    Int J Oncol. 2026;68:19.
    PubMed         Abstract available
    
    

    
    Mol Ther Oncol

29. MOHIUDDIN TM, Zhang C, Sheng W, Al-Rawe M, et al
    Near-infrared photoimmunotherapy for effective elimination of ovarian cancer cells by inducing immunogenic cell death.
    Mol Ther Oncol. 2025;33:201086.
    PubMed         Abstract available
    
    

    
    Oncogene

30. LI Q, Zhang S, Wang M, Yi Q, et al
    Correction: Activated MAFB in ovarian cancer promotes cytoskeletal remodeling and immune microenvironment suppression by interfering with m6A modifications through WTAP competition.
    Oncogene. 2025 Dec 5. doi: 10.1038/s41388-025-03656.
    PubMed        
    
    

    
    Oncology (Williston Park)

31. ANDREA I NANEZ MD, Velez MA, Mae Zakhour Md, Garon EB, et al
    Differences in Clinical Trial Availability vs Distribution of Disease Among Gynecological Cancers.
    Oncology (Williston Park). 2025;39:456-462.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.